Abstract
Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.
As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.
Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Keywords: Antiplatelets, stroke, prevention.
Current Vascular Pharmacology
Title:Antiplatelets in Stroke Prevention
Volume: 11 Issue: 6
Author(s): Antonio Pinto, Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Butta and Giuseppe Licata
Affiliation:
Keywords: Antiplatelets, stroke, prevention.
Abstract: Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.
As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.
Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Export Options
About this article
Cite this article as:
Pinto Antonio, Raimondo Di Domenico, Tuttolomondo Antonino, Butta Carmelo and Licata Giuseppe, Antiplatelets in Stroke Prevention, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128112915
DOI https://dx.doi.org/10.2174/157016111106140128112915 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Involvement of the ADAM 12 in Thrombin-Induced Rat's VSMCs Proliferation
Current Medicinal Chemistry The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism Potential Role of Endothelin in Early Vascular Aging
Current Hypertension Reviews Quantitative Determination and Validation of Four Phenolic Acids in <i>Salvia Miltiorrhiza</i> Bunge using <sup>1</sup>H-NMR Spectroscopy
Current Pharmaceutical Analysis Subject Index to Volume 5
Current Drug Targets Aging in the Perspective of Integrative Medicine, Psychoneuroendocrineimmunology and Hormesis
Current Aging Science Sequential Bilateral Internal Jugular Vein Thrombosis: A Case Report and Review of this Rare Medical Entity
Vascular Disease Prevention (Discontinued) Nanoparticulate Iron Oxide Contrast Agents for Untargeted and Targeted Cardiovascular Magnetic Resonance Imaging
Current Nanoscience The Intermediate-Conductance Ca2+-Activated K+ Channel (KCa3.1) in Vascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Advances in Sickle Cell Disease Treatment: from Drug Discovery Until the Patient Monitoring
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature
Current Cardiology Reviews Inflammatory Cytokines and Cardiovascular Disease
Current Drug Targets - Inflammation & Allergy Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Combinations of Renin-Angiotensin-Aldosterone System Antagonists:True Advantages?
Current Pharmaceutical Design Novel Fibrinogen Receptor Antagonists - RGDF Mimetics, 4-(1,2,3,4- tetrahydro-isoquinoline-7-yl)amino-4-oxo-butyric Acid Derivatives
Medicinal Chemistry Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology